Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

Venetoclax Is Safe and Tolerable As Post-Transplant Maintenance Therapy for AML Patients at High Risk for Relapse

Andrew Kent, MD PhD, Daniel A. Pollyea, Amanda Winters, MDPhD, Craig T. Jordan, PhD, Clayton Smith, MD, Jonathan A. Gutman, MD

Blood (2020) 136 (Supplement 1): 11–12.

https://doi.org/10.1182/blood-2020-138832

Published: 2020

Journal Articles

Venetoclax and Azacitidine for Newly Diagnosed Non-Elderly Adult Patients with Acute Myeloid Leukemia and Adverse Risk Features

Jonathan A. Gutman, MD, Amanda Winters, MDPhD, Maria L Amaya, MD PhD, Christine M. McMahon, MD, Jeffrey Schowinsky, MD, Diana Abbott, PhD, Andrew Hammes, MS, Shanshan Pei, PhD, Brett M. Stevens, PhD, Craig T. Jordan, PhD, Clayton Smith, MD, Daniel A. Pollyea

Blood (2020) 136 (Supplement 1): 9.

https://doi.org/10.1182/blood-2020-136120

Published: 2020

Journal Articles

Allogeneic Transplant Improves AML Outcomes Compared to Maintenance Venetoclax and Azacitidine Following Response to Initial Venetoclax and Azacitidine Therapy

Daniel A. Pollyea, Amanda Winters, MDPhD, Craig T. Jordan, PhD, Clayton Smith, MD, Jonathan A. Gutman, MD

Blood (2020) 136 (Supplement 1): 24.

https://doi.org/10.1182/blood-2020-138821

Published: 2020

Journal Articles

A Single-Arm, Open-Label Phase 1 Study of Itacitinib (ITA) with Calcineurin Inhibitor (CNI)-Based Interventions for Prophylaxis of Graft-Versus-Host Disease (GVHD; GRAVITAS-119)

Hannah Choe, MD, Nirav N. Shah, MD, Patrice Chevallier, MD PhD, Marie Thérèse Rubio, MD PhD, Mark A. Schroeder, MD, Nancy M. Hardy, MD, Patrick J. Stiff, MD, Carlos Solano, MD PhD, Ibrahim Yakoub-Agha, Jonathan A. Gutman, MD, Scott D. Rowley, MD, Maria Caterina Mico', MD, Elisabetta Terruzzi, MD, Rafael F. Duarte, MD PhD FRCP, Rodica Morariu-Zamfir, MD, Michael Arbushites, Kai Ding, PhD, Miguel-Angel Perales, MD

Blood (2020) 136 (Supplement 1): 50–51.

https://doi.org/10.1182/blood-2020-140747

Published: 2020

Journal Articles

A Phase 2 Study of Glasdegib for the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients with High Risk of Post-Allogeneic Stem Cell Transplantation Relapse

Andrew Kent, MD PhD, Sumithira Vasu, MDMBBS, Derek Schatz, Natalie Monson, Steven Devine, MD, Clayton Smith, MD, Jonathan A Gutman, MD, Daniel A Pollyea, MD

Blood (2019) 134 (Supplement_1): 1311.

https://doi.org/10.1182/blood-2019-127418

Published: 2019

Journal Articles

Outcomes Following Allogeneic Stem Cell Transplantation for AML in First Completion Remission Are Comparable between MRD Negative Patients and MRD Positive Patients Receiving Induction Only and Are Superior to MRD Positive Patients Receiving Induction and Additional Therapy

Jonathan A Gutman, MD, Prashant Sharma, MD, Enkhtsetseg Purev, MD, Clayton Smith, MD, Amanda Winters, MD PhD, Andrew Hammes, MS, Michael R. Loken, PhD, Daniel A Pollyea, MD

Blood (2019) 134 (Supplement_1): 4615.

https://doi.org/10.1182/blood-2019-129150

Published: 2019

Journal Articles

No Engraftment Advantage after Single or Double Umbilical Cord Blood Transplant (CBT) with the Addition of a Non-HLA Matched Off-the-Shelf Expanded Cord Blood Unit Compared to Conventional CBT: Results of a Randomized Trial

Filippo Milano, MD PhD, Andrew R Rezvani, MD, Joanne Kurtzberg, MD, Chatchada Karanes, MD, Jonathan A Gutman, MD, Christine Duncan, MD, Alla Keyzner, MD, Rabi Hanna, MD, Tonya Kimberly Marmon, PhD, Ann Dahlberg, MD, Colleen Delaney, MD MSc

Blood (2019) 134 (Supplement_1): 146.

https://doi.org/10.1182/blood-2019-130716

Published: 2019

Journal Articles

Developmental Plasticity of Acute Myeloid Leukemia Mediates Resistance to Venetoclax-Based Therapy

Blood (2019) 134 (Supplement_1): 185.

https://doi.org/10.1182/blood-2019-131390

Published: 2019

Journal Articles

How Median Follow-up Time Informs Survival Outcomes: Lessons from a Trial of Acute Myeloid Patients Treated with Venetoclax and Azacitidine

Diana Abbott, PhD, Andrew Hammes, MS, Jonathan A Gutman, MD, Daniel A Pollyea, MD, Clayton Smith, MD

Blood (2019) 134 (Supplement_1): 5897.

https://doi.org/10.1182/blood-2019-126344

Published: 2019

Journal Articles

Venetoclax and Azacitidine for Older Newly Diagnosed Patients with Acute Myeloid Leukemia: A Single-Institution Pilot Study Using Measurable Residual Disease to Guide Therapy

Blood (2019) 134 (Supplement_1): 2638.

https://doi.org/10.1182/blood-2019-122120

Published: 2019

Journal Articles

Relapsed Acute Myeloid Leukemia Is Less Sensitive to Venetoclax + Azacitidine Due to Leukemia Stem Cell Resistance Driven By Fatty Acid Metabolism and Can be Overcome By Pharmacologic Inhibition of CPT1

Daniel A Pollyea, MD, Courtney L Jones, PhD, Brett M Stevens, PhD, Shanshan Pei, PhD, Angelo D'Alessandro, PhD, Rachel Culp-Hill, BS, Diana Abbott, PhD, Andrew Hammes, MS, James Dugan, MD, Jonathan A Gutman, MD, Enkhtsetseg Purev, MD PhD, Clayton Smith, MD, Craig T Jordan, PhD

Blood (2018) 132 (Supplement 1): 432.

https://doi.org/10.1182/blood-2018-99-111507

Published: 2018

Journal Articles

Post Transplant Prophylaxis with High Dose Valacyclovir through Day 100 Versus Day of Post Transplant Hospital Discharge Decreases Cytomegalovirus Reactivation in Adult Umbilical Cord Blood Transplant Recipients

Prashant Sharma, MD, Jennifer MacDonald, Jeff Kaiser, Jennifer Tobin, Matthew Miller, Maheen Abidi, MD, Esther Benamu, MD, Enkhtsetseg Purev, MD PhD, Bradley M. Haverkos, MD MPH, MS, Jonathan A Gutman, MD

Blood (2018) 132 (Supplement 1): 4659.

https://doi.org/10.1182/blood-2018-99-110211

Published: 2018

Journal Articles

Chronic Graft Versus Host Disease Burden and Relapse Rates Are Lower with Comparable Overall Survival and Graft Versus Host Disease Free, Relapse Free Survival Following Adult Umbilical Cord Blood Compared to Matched Sibling Peripheral Blood Stem Cell Transplantation

Prashant Sharma, MD, Enkhtsetseg Purev, MD PhD, Bradley M. Haverkos, MD MPH, MS, Daniel A Pollyea, MD, Clayton Smith, MD, Manali Kamdar, Daniel W Sherbenou, MD PhD, Tomer M Mark, MD MS, Peter A Forsberg, MD, Jonathan A Gutman, MD

Blood (2018) 132 (Supplement 1): 4660.

https://doi.org/10.1182/blood-2018-99-119690

Published: 2018

Journal Articles

Tracking of AML-Associated Mutations Via Droplet Digital PCR Is Predictive of Outcomes Post-Transplant

Amanda Winters, MD PhD, Madeline Goosman, Brett M Stevens, PhD, Enkhtsetseg Purev, MD PhD, Clayton Smith, MD, Daniel A Pollyea, MD, Craig T Jordan, PhD, Jonathan A Gutman, MD

Blood (2018) 132 (Supplement 1): 2138.

https://doi.org/10.1182/blood-2018-99-110834

Published: 2018

Journal Articles

Clinical Outcomes of Catheter-Associated Venous Thrombosis in the Post-Hematopoietic Stem Cell Transplant Setting

Genevieve Moyer, MD, Jonathan A Gutman, MD, Jorge Di Paola, MD, Tyler W. Buckner, MD MSc

Blood (2017) 130 (Supplement 1): 4901.

https://doi.org/10.1182/blood.V130.Suppl_1.4901.4901

Published: 2017

Journal Articles

Venetoclax (Ven) with Azacitidine (Aza) for Untreated Elderly Acute Myeloid Leukemia (AML) Patients (Pts) Unfit for Induction Chemotherapy: Single Center Clinical Experience and Mechanistic Insights from Correlative Studies

Daniel A. Pollyea, MD, Brett M. Stevens, PhD, Amanda Winters, MD PhD, Mohd Minhajuddin, PhD, Jonathan A Gutman, MD, Enkhtsetseg Purev, MD PhD, Clayton Smith, MD FRCPC, Diana Abbott, PhD, Craig T. Jordan, PhD

Blood (2017) 130 (Supplement 1): 181.

https://doi.org/10.1182/blood.V130.Suppl_1.181.181

Published: 2017

Journal Articles

Sequential Azacitidine (Aza) and Lenalidomide (Len) for Patients (Pts) with Relapsed and Refractory (R/R) Acute Myeloid Leukemia (AML): Clinical Results and Predictive Modeling Using Computational Analysis and Serial Genomics

Brett M. Stevens, PhD, Amanda Winters, MD PhD, Jonathan A Gutman, MD, Aaron Fullerton, BS, Gregory Hemenway, MS2, Nicholas Miltgen, BS, Qi Wei, MD, Taher Abbasi, MS, MBA, Shireen Vali, PhD, Neeraj Kumar Singh, B.Tech, Leylah M. Drusbosky, PhD, Chris R. Cogle, MD, Andrew Hammes, MS, Craig T. Jordan, PhD, Daniel A. Pollyea, MD

Blood (2017) 130 (Supplement 1): 1337.

https://doi.org/10.1182/blood.V130.Suppl_1.1337.1337

Published: 2017

Journal Articles

Checkpoint Blockade for Treatment of Relapsed Lymphoma Following Allogeneic Hematopoietic Cell Transplant: Use May be Complicated By Onset of Severe Acute Graft Versus Host Disease

Blood (2016) 128 (22): 1163.

https://doi.org/10.1182/blood.V128.22.1163.1163

Published: 2016

Journal Articles

Sirolimus Combined with Mycophenolate Mofetil (MMF) and Cyclosporine (CSP) Significantly Improves Prevention of Acute Graft-Versus-Host-Disease (GVHD) after Unrelated Hematopoietic Cell Transplantation (HCT): Results from a Phase III Randomized Multi-Center Trial

Brenda M Sandmaier, MD, David G Maloney, MD PhD, Barry E. Storer, PhD, Gitte Olesen, MD, Michael B. Maris, MD, Jonathan A Gutman, MD, Soren Lykke Petersen, MD DMSC, Amelia Langston, MD, Thomas Chauncey, Wolfgang Bethge, MD, Michael A Pulsipher, MD, Brian Thomas Kornblit, MD PhD, Ann E Woolfrey, MD, Marco Mielcarek, MD, Paul J. Martin, MD, Mary E.D. Flowers, MD, Rainer F. Storb, MD

Blood (2016) 128 (22): 506.

https://doi.org/10.1182/blood.V128.22.506.506

Published: 2016

Journal Articles

Late Reversal of Dominance after Dual Cord Blood Transplantation

Mary Berg, MD, Jonathan A Gutman, MD, Leslie Vinson, MT(ASCP), SBB, Nicole Draper, MD

Blood (2016) 128 (22): 5796.

https://doi.org/10.1182/blood.V128.22.5796.5796

Published: 2016

NARROW

Venetoclax Is Safe and Tolerable As Post-Transplant Maintenance Therapy for AML Patients at High Risk for Relapse

Venetoclax and Azacitidine for Newly Diagnosed Non-Elderly Adult Patients with Acute Myeloid Leukemia and Adverse Risk Features

Allogeneic Transplant Improves AML Outcomes Compared to Maintenance Venetoclax and Azacitidine Following Response to Initial Venetoclax and Azacitidine Therapy

A Single-Arm, Open-Label Phase 1 Study of Itacitinib (ITA) with Calcineurin Inhibitor (CNI)-Based Interventions for Prophylaxis of Graft-Versus-Host Disease (GVHD; GRAVITAS-119)

A Phase 2 Study of Glasdegib for the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients with High Risk of Post-Allogeneic Stem Cell Transplantation Relapse

Outcomes Following Allogeneic Stem Cell Transplantation for AML in First Completion Remission Are Comparable between MRD Negative Patients and MRD Positive Patients Receiving Induction Only and Are Superior to MRD Positive Patients Receiving Induction and Additional Therapy

No Engraftment Advantage after Single or Double Umbilical Cord Blood Transplant (CBT) with the Addition of a Non-HLA Matched Off-the-Shelf Expanded Cord Blood Unit Compared to Conventional CBT: Results of a Randomized Trial

Developmental Plasticity of Acute Myeloid Leukemia Mediates Resistance to Venetoclax-Based Therapy

How Median Follow-up Time Informs Survival Outcomes: Lessons from a Trial of Acute Myeloid Patients Treated with Venetoclax and Azacitidine

Venetoclax and Azacitidine for Older Newly Diagnosed Patients with Acute Myeloid Leukemia: A Single-Institution Pilot Study Using Measurable Residual Disease to Guide Therapy

Relapsed Acute Myeloid Leukemia Is Less Sensitive to Venetoclax + Azacitidine Due to Leukemia Stem Cell Resistance Driven By Fatty Acid Metabolism and Can be Overcome By Pharmacologic Inhibition of CPT1

Post Transplant Prophylaxis with High Dose Valacyclovir through Day 100 Versus Day of Post Transplant Hospital Discharge Decreases Cytomegalovirus Reactivation in Adult Umbilical Cord Blood Transplant Recipients

Chronic Graft Versus Host Disease Burden and Relapse Rates Are Lower with Comparable Overall Survival and Graft Versus Host Disease Free, Relapse Free Survival Following Adult Umbilical Cord Blood Compared to Matched Sibling Peripheral Blood Stem Cell Transplantation

Tracking of AML-Associated Mutations Via Droplet Digital PCR Is Predictive of Outcomes Post-Transplant

Clinical Outcomes of Catheter-Associated Venous Thrombosis in the Post-Hematopoietic Stem Cell Transplant Setting

Venetoclax (Ven) with Azacitidine (Aza) for Untreated Elderly Acute Myeloid Leukemia (AML) Patients (Pts) Unfit for Induction Chemotherapy: Single Center Clinical Experience and Mechanistic Insights from Correlative Studies

Sequential Azacitidine (Aza) and Lenalidomide (Len) for Patients (Pts) with Relapsed and Refractory (R/R) Acute Myeloid Leukemia (AML): Clinical Results and Predictive Modeling Using Computational Analysis and Serial Genomics

Checkpoint Blockade for Treatment of Relapsed Lymphoma Following Allogeneic Hematopoietic Cell Transplant: Use May be Complicated By Onset of Severe Acute Graft Versus Host Disease

Sirolimus Combined with Mycophenolate Mofetil (MMF) and Cyclosporine (CSP) Significantly Improves Prevention of Acute Graft-Versus-Host-Disease (GVHD) after Unrelated Hematopoietic Cell Transplantation (HCT): Results from a Phase III Randomized Multi-Center Trial

Late Reversal of Dominance after Dual Cord Blood Transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only